Bronchodilators in cystic fibrosis. [J R Soc Med. 2000] - PubMed

loading

Review Inhaled bronchodilators for cystic fibrosis. [Cochrane Database Syst Rev. 2005]
Review Inhaled bronchodilators for cystic fibrosis.
Halfhide C, Evans HJ, Couriel J. Cochrane Database Syst Rev. 2005 Oct 19; (4):CD003428. Epub 2005 Oct 19.
Long acting bronchodilators in chronic obstructive pulmonary disease. [N Z Med J. 1997]
Long acting bronchodilators in chronic obstructive pulmonary disease.
Griffiths I. N Z Med J. 1997 Oct 24; 110(1054):402-3.
Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. [Am J Respir Crit Care Med. 2001]
Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Am J Respir Crit Care Med. 2001 Apr; 163(5):1087-92.
Effect of albuterol on maximal exercise capacity in cystic fibrosis. [Chest. 2007]
Effect of albuterol on maximal exercise capacity in cystic fibrosis.
Serisier DJ, Coates AD, Bowler SD. Chest. 2007 Apr; 131(4):1181-7.
Review Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. [Drugs Aging. 2001]
Review Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B, Markham A. Drugs Aging. 2001; 18(6):441-72.

Review Physiotherapy in infants and young children with cystic fibrosis: current practice and future developments. [J R Soc Med. 2004]
Review Physiotherapy in infants and young children with cystic fibrosis: current practice and future developments.
Lannefors L, Button BM, McIlwaine M. J R Soc Med. 2004; 97 Suppl 44:8-25.
Review Asthma in cystic fibrosis. [J R Soc Med. 2003]
Review Asthma in cystic fibrosis.
Balfour-Lynn IM. J R Soc Med. 2003; 96 Suppl 43:30-4.
Review "CF asthma": what is it and what do we do about it? [Thorax. 2002]
Review "CF asthma": what is it and what do we do about it?
Balfour-Lynn IM, Elborn JS. Thorax. 2002 Aug; 57(8):742-8.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Bronchodilators in cystic fibrosis.
Bronchodilators in cystic fibrosis.
J R Soc Med. 2000 ;93 Suppl 38:37-9.

PubMed
Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin ...
Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone.
Am J Psychiatry. 1975 Apr ;132(4):447-50.

PubMed
Signal transduction pathways of G protein-coupled receptors and their cross-talk...
Signal transduction pathways of G protein-coupled receptors and their cross-talk with receptor tyrosine kinases: lessons from bradykinin signaling.
Curr Med Chem. 2000 Sep ;7(9):911-43.

PubMed
Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting ...
Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression.
Carcinogenesis. 2000 Aug ;21(8):1619-22.

PubMed
A potential mechanism for fumonisin B(1)-mediated hepatocarcinogenesis: cyclin D...
A potential mechanism for fumonisin B(1)-mediated hepatocarcinogenesis: cyclin D1 stabilization associated with activation of Akt and inhibition of GSK-3beta activity.
Carcinogenesis. 2000 Aug ;21(8):1537-46.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed